Related Experiment Videos
Corticosteroids for idiopathic pulmonary fibrosis
L Richeldi1, H R Davies, G Ferrara
1Divisione di Pneumologia, Policlinico di Modena, Via del Pozzo, 71, Modena, Italy.
The Cochrane Database of Systematic Reviews
|August 15, 2003
Summary
Current treatments for Idiopathic Pulmonary Fibrosis (IPF) using corticosteroids lack evidence of efficacy. Further research into immunomodulatory therapies is recommended for this lethal lung disease.
Area of Science:
- Pulmonology
- Rheumatology
- Internal Medicine
Background:
- Idiopathic Pulmonary Fibrosis (IPF), also known as cryptogenic fibrosing alveolitis (CFA), is a fatal lung disease with a poor prognosis.
- Current standard therapy involves systemic corticosteroids, despite a lack of proven efficacy.
- Emerging research suggests aberrant wound healing, not inflammation, is central to IPF pathogenesis, questioning corticosteroid rationale.
Purpose of the Study:
- To evaluate the effectiveness of corticosteroid treatment in adult patients diagnosed with Idiopathic Pulmonary Fibrosis (IPF).
Main Methods:
- Searched major databases (Cochrane Library, MEDLINE, EMBASE) and reference lists for relevant trials.
- Included Randomized Controlled Trials (RCTs) and Controlled Clinical Trials (CCTs) assessing corticosteroids alone in adults with IPF.
- Full texts were retrieved for eligible studies; quality assessment was planned but not performed due to lack of suitable studies.
Main Results:
- Fifteen studies were initially identified as potentially eligible for meta-analysis.
- No RCTs or CCTs met the inclusion criteria after full-text review.
- Consequently, no data could be included in a meta-analysis, and all studies were excluded due to methodological limitations.
Conclusions:
- There is currently no evidence to support the use of corticosteroids for treating Idiopathic Pulmonary Fibrosis (IPF) or usual interstitial pneumonia (UIP).
- Future RCTs evaluating corticosteroids for IPF are unlikely given evolving understanding of its pathogenesis.
- Accurate diagnosis is crucial, as other interstitial pneumonias may respond to corticosteroids; immunomodulatory therapies may offer more promise for IPF/UIP treatment.